Environmental Science & Technology Letters Environ.最新文献

{"title":"In-hospital initiation of angiotensin receptor-neprilysin inhibition in acute heart failure: the PREMIER trial.","authors":"Atsushi Tanaka, Keisuke Kida, Yuya Matsue, Takumi Imai, Satoru Suwa, Isao Taguchi, Itaru Hisauchi, Hiroki Teragawa, Yoshiyuki Yazaki, Masao Moroi, Koichi Ohashi, Daisuke Nagatomo, Toru Kubota, Takeshi Ijichi, Yuji Ikari, Keisuke Yonezu, Naohiko Takahashi, Shigeru Toyoda, Tsutomu Toshida, Hiroshi Suzuki, Tohru Minamino, Kazutaka Nogi, Kazuki Shiina, Yu Horiuchi, Kengo Tanabe, Daisuke Hachinohe, Shunsuke Kiuchi, Kenya Kusunose, Michio Shimabukuro, Koichi Node","doi":"10.1093/eurheartj/ehae561","DOIUrl":"10.1093/eurheartj/ehae561","url":null,"abstract":"<p><strong>Background and aims: </strong>The efficacy and safety of early sacubitril/valsartan (Sac/Val) initiation after acute heart failure (AHF) has not been demonstrated outside North America. The present study aimed to evaluate the effect of in-hospital Sac/Val therapy initiation after an AHF episode on N-terminal pro-B-type natriuretic peptide (NT-proBNP) level in Japanese patients.</p><p><strong>Methods: </strong>This was an investigator-initiated, multicentre, prospective, randomized, open-label, blinded-endpoint pragmatic trial. After haemodynamic stabilization within 7 days after hospitalization, eligible inpatients were allocated to switch from angiotensin-converting enzyme inhibitor or angiotensin receptor blocker to Sac/Val (Sac/Val group) or to continue angiotensin-converting enzyme inhibitor or angiotensin receptor blocker (control group). The primary efficacy endpoint was the 8-week proportional change in geometric means of NT-proBNP levels.</p><p><strong>Results: </strong>A total of 400 patients were equally randomized, and 376 (median age 75 years, 31.9% women, de novo heart failure rate 55.6%, and median left ventricular ejection fraction 37%) were analysed. The per cent changes in NT-proBNP level geometric means at Weeks 4/8 were -35%/-45% (Sac/Val group) and -18%/-32% (control group), and their group ratio (Sac/Val vs. control) was 0.80 (95% confidence interval 0.68-0.94; P = .008) at Week 4 and 0.81 (95% confidence interval 0.68-0.95; P = .012) at Week 8, respectively. In the pre-specified subgroup analyses, the effects of Sac/Val were confined to patients with a left ventricular ejection fraction < 40% and were more evident in those in sinus rhythm and taking mineralocorticoid receptor antagonists. No adverse safety signal was evident.</p><p><strong>Conclusions: </strong>In-hospital Sac/Val therapy initiation in addition to contemporary recommended therapy triggered a greater NT-proBNP level reduction in Japanese patients hospitalized for AHF. These findings may expand the evidence on Sac/Val therapy in this clinical situation outside North America.</p><p><strong>Clinical trial registration: </strong>ClinicalTrial.gov (NCT05164653) and Japan Registry of Clinical Trials (jRCTs021210046).</p>","PeriodicalId":37,"journal":{"name":"Environmental Science & Technology Letters Environ.","volume":" ","pages":"4482-4493"},"PeriodicalIF":37.6,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11544311/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142105688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"环境科学与生态学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intravenous iron therapy results in rapid and sustained rise in myocardial iron content through a novel pathway.","authors":"Mayra Vera-Aviles, Syeeda Nashitha Kabir, Akshay Shah, Paolo Polzella, Dillon Yee Lim, Poppy Buckley, Charlotte Ball, Dorine Swinkels, Hanke Matlung, Colin Blans, Philip Holdship, Jeremy Nugent, Edward Anderson, Michael Desborough, Stefan Piechnik, Vanessa Ferreira, Samira Lakhal-Littleton","doi":"10.1093/eurheartj/ehae359","DOIUrl":"10.1093/eurheartj/ehae359","url":null,"abstract":"<p><strong>Background and aims: </strong>Intravenous iron therapies contain iron-carbohydrate complexes, designed to ensure iron becomes bioavailable via the intermediary of spleen and liver reticuloendothelial macrophages. How other tissues obtain and handle this iron remains unknown. This study addresses this question in the context of the heart.</p><p><strong>Methods: </strong>A prospective observational study was conducted in 12 patients receiving ferric carboxymaltose (FCM) for iron deficiency. Myocardial, spleen, and liver magnetic resonance relaxation times and plasma iron markers were collected longitudinally. To examine the handling of iron taken up by the myocardium, intracellular labile iron pool (LIP) was imaged in FCM-treated mice and cells.</p><p><strong>Results: </strong>In patients, myocardial relaxation time T1 dropped maximally 3 h post-FCM, remaining low 42 days later, while splenic T1 dropped maximally at 14 days, recovering by 42 days. In plasma, non-transferrin-bound iron (NTBI) peaked at 3 h, while ferritin peaked at 14 days. Changes in liver T1 diverged among patients. In mice, myocardial LIP rose 1 h and remained elevated 42 days after FCM. In cardiomyocytes, FCM exposure raised LIP rapidly. This was prevented by inhibitors of NTBI transporters T-type and L-type calcium channels and divalent metal transporter 1.</p><p><strong>Conclusions: </strong>Intravenous iron therapy with FCM delivers iron to the myocardium rapidly through NTBI transporters, independently of reticuloendothelial macrophages. This iron remains labile for weeks, reflecting the myocardium's limited iron storage capacity. These findings challenge current notions of how the heart obtains iron from these therapies and highlight the potential for long-term dosing to cause cumulative iron build-up in the heart.</p>","PeriodicalId":37,"journal":{"name":"Environmental Science & Technology Letters Environ.","volume":" ","pages":"4497-4508"},"PeriodicalIF":37.6,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11544312/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141450191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"环境科学与生态学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implementing medical therapy during worsening heart failure.","authors":"Ankeet S Bhatt, Muthiah Vaduganathan","doi":"10.1093/eurheartj/ehae566","DOIUrl":"10.1093/eurheartj/ehae566","url":null,"abstract":"","PeriodicalId":37,"journal":{"name":"Environmental Science & Technology Letters Environ.","volume":" ","pages":"4494-4496"},"PeriodicalIF":37.6,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142105686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"环境科学与生态学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mucolipidosis III: a rare phenocopy of inherited metabolic cardiomyopathy.","authors":"Xia Gu, Linlin Dai, Minjie Lu","doi":"10.1093/eurheartj/ehae636","DOIUrl":"10.1093/eurheartj/ehae636","url":null,"abstract":"","PeriodicalId":37,"journal":{"name":"Environmental Science & Technology Letters Environ.","volume":" ","pages":"4548"},"PeriodicalIF":37.6,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"环境科学与生态学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A similar severe fibrosis pattern in a monozygotic twin pair with the TRIM63 variant manifesting as hypertrophic cardiomyopathy.","authors":"Lutong Pu, Jie Wang, Yucheng Chen","doi":"10.1093/eurheartj/ehae607","DOIUrl":"10.1093/eurheartj/ehae607","url":null,"abstract":"","PeriodicalId":37,"journal":{"name":"Environmental Science & Technology Letters Environ.","volume":" ","pages":"4546-4547"},"PeriodicalIF":37.6,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142371297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"环境科学与生态学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evolving therapeutic approaches to aortic stenosis, tricuspid regurgitation, hypertrophic cardiomyopathy, and acute heart failure.","authors":"Filippo Crea","doi":"10.1093/eurheartj/ehae752","DOIUrl":"https://doi.org/10.1093/eurheartj/ehae752","url":null,"abstract":"","PeriodicalId":37,"journal":{"name":"Environmental Science & Technology Letters Environ.","volume":"45 42","pages":"4451-4455"},"PeriodicalIF":37.6,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142603295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"环境科学与生态学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trial.","authors":"Caroline J Coats, Ahmad Masri, Roberto Barriales-Villa, Theodore P Abraham, Douglas Marshall Brinkley, Brian L Claggett, Albert Hagege, Sheila M Hegde, Carolyn Y Ho, Ian J Kulac, Matthew M Y Lee, Martin S Maron, Iacopo Olivotto, Anjali T Owens, Scott D Solomon, Jacob Tfelt-Hansen, Hugh Watkins, Daniel L Jacoby, Stephen B Heitner, Stuart Kupfer, Fady I Malik, Lisa Meng, Amy Wohltman, James L Januzzi","doi":"10.1093/eurheartj/ehae590","DOIUrl":"10.1093/eurheartj/ehae590","url":null,"abstract":"<p><strong>Background and aims: </strong>The role of biomarker testing in the management of obstructive hypertrophic cardiomyopathy is not well defined. This pre-specified analysis of SEQUOIA-HCM (NCT05186818) sought to define the associations between clinical characteristics and baseline concentrations of N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin I (hs-cTnI), and to evaluate the effect of treatment with aficamten on biomarker concentrations.</p><p><strong>Methods: </strong>Cardiac biomarkers were measured at baseline and serially throughout the study. Regression analyses determined predictors of baseline NT-proBNP and hs-cTnI concentrations, and evaluated whether early changes in these biomarkers relate to later changes in left ventricular outflow tract gradient (LVOT-G), other echocardiographic measures, health status, and functional capacity.</p><p><strong>Results: </strong>Baseline concentration of NT-proBNP was associated with LVOT-G and measures of diastolic function, while hs-cTnI was associated with left ventricular thickness. Within 8 weeks of treatment with aficamten, NT-proBNP was reduced by 79% (95% confidence interval 76%-83%, P < .001) and hs-cTnI by 41% (95% confidence interval 32%-49%, P < .001); both biomarkers reverted to baseline after washout. Reductions in NT-proBNP and hs-cTnI by 24 weeks were strongly associated with a lowering of LVOT-G, improvement in health status, and increased peak oxygen uptake. N-Terminal pro-B-type natriuretic peptide reduction strongly correlated with the majority of improvements in exercise capacity. Furthermore, the change in NT-proBNP by Week 2 was associated with the 24-week change in key endpoints.</p><p><strong>Conclusions: </strong>N-Terminal pro-B-type natriuretic peptide and hs-cTnI concentrations are associated with key variables in obstructive hypertrophic cardiomyopathy. Serial measurement of NT-proBNP and hs-cTnI appears to reflect clinical response to aficamten therapy.</p>","PeriodicalId":37,"journal":{"name":"Environmental Science & Technology Letters Environ.","volume":" ","pages":"4464-4478"},"PeriodicalIF":37.6,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11544315/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142105667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"环境科学与生态学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Natriuretic peptides and cardiac hs-troponins as surrogates of cardiomyocyte stress: clinical value in hypertrophic cardiomyopathy?","authors":"Evangelos Giannitsis, Norbert Frey, Hugo A Katus","doi":"10.1093/eurheartj/ehae600","DOIUrl":"10.1093/eurheartj/ehae600","url":null,"abstract":"","PeriodicalId":37,"journal":{"name":"Environmental Science & Technology Letters Environ.","volume":" ","pages":"4479-4481"},"PeriodicalIF":37.6,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142105696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"环境科学与生态学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Benefit of isolated surgical valve repair or replacement for functional tricuspid regurgitation and long-term outcomes stratified by the TRI-SCORE.","authors":"Julien Dreyfus, Fernando Juarez-Casso, Alessandra Sala, Manuel Carnero-Alcazar, Andrea Eixerés-Esteve, Yohann Bohbot, Baptiste Bazire, Michele Flagiello, Elisabeth Riant, Yannick Mbaki, Jacques Tomasi, Thomas Senage, Kenza Rahmouni El Idrissi, Augustin Coisne, Damien Eyharts, Fabien Doguet, Florence Viau, Florian Eggenspieler, Samuel Heuts, Peyman Sardari Nia, Gregor Heitzinger, Xavier Galloo, Nina Ajmone Marsan, Giovanni Benfari, Luigi Badano, Denisa Muraru, Francesco Maisano, Yan Topilsky, Hector Michelena, Maurice Enriquez-Sarano, Jeroen Bax, Philipp Bartko, Christine Selton-Suty, Gilbert Habib, Yoan Lavie-Badie, Thomas Modine, Vincent Chan, Thierry Le Tourneau, Erwan Donal, Pascal Lim, Costin Radu, Jordan Bernick, George A Wells, Christophe Tribouilloy, Bernard Iung, Jean-François Obadia, Michele De Bonis, Juan Crestanello, David Messika-Zeitoun","doi":"10.1093/eurheartj/ehae578","DOIUrl":"10.1093/eurheartj/ehae578","url":null,"abstract":"<p><strong>Background and aims: </strong>Severe tricuspid regurgitation is associated with increased mortality rates, but benefit of its correction and ideal timing are not clearly determined. This study aimed to identify patient subsets who might benefit from the surgery.</p><p><strong>Methods: </strong>In TRIGISTRY, an international cohort study of consecutive patients with severe isolated functional tricuspid regurgitation (33 centres, 10 countries), survival rates up to 10 years were compared between patients who underwent isolated tricuspid valve surgery (repair or replacement) and those conservatively managed, overall and according to TRI-SCORE category (low: ≤3, intermediate: 4-5, and high: ≥6).</p><p><strong>Results: </strong>One thousand and two hundred seventeen were managed conservatively, and 551 underwent isolated tricuspid valve surgery (200 repairs and 351 replacements). TRI-SCORE distribution was 33% low, 32% intermediate, and 35% high. At 10 years, survival rates were similar between surgical and conservative management [41% vs. 36%; hazard ratio (HR) .97; 95% confidence interval (CI) .88-1.08, P = .57]. Surgery improved survival compared with conservative management in the low TRI-SCORE category (72% vs. 44%; HR .27; 95% CI .20-.37, P < .0001), but not in the intermediate (36% vs. 37%; HR 1.17; 95%CI .98-1.40, P = .09) or high categories (20% vs. 24%; HR 1.06; 95% CI .91-1.25, P = .45). Both repair and replacement improved survival in the low TRI-SCORE category (84% and 61% vs. 44%; HR .11; 95% CI .06-.19, P < .0001, and HR .65; 95% CI .47-.90, P = .009). Repair showed benefit in the intermediate category (59% vs. 37%; HR .49; 95% CI .35-.68, P < .0001) while replacement was possibly harmful (25% vs. 37%; HR 1.43; 95% CI 1.18-1.72, P = .0002).</p><p><strong>Conclusions: </strong>Higher survival rates were observed with repair than replacement and benefit of intervention declined as TRI-SCORE increased with no benefit of any type of surgery in the high TRI-SCORE category. These results emphasize the importance of timely intervention and patient selection to achieve the best outcomes and the need for randomized controlled trials.</p>","PeriodicalId":37,"journal":{"name":"Environmental Science & Technology Letters Environ.","volume":" ","pages":"4512-4522"},"PeriodicalIF":37.6,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142105664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"环境科学与生态学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Benefit of early aortic valve replacement in asymptomatic severe aortic stenosis but questions remain.","authors":"Andreas Martinsson, Anders Jeppsson","doi":"10.1093/eurheartj/ehae597","DOIUrl":"10.1093/eurheartj/ehae597","url":null,"abstract":"","PeriodicalId":37,"journal":{"name":"Environmental Science & Technology Letters Environ.","volume":" ","pages":"4536-4538"},"PeriodicalIF":37.6,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142105689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"环境科学与生态学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}